63854-31-9

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-Trifluoromethylphenyl)-piperazine is used as a key intermediate in the synthesis of pharmaceutical drugs for its potential as a serotonin receptor agonist. Its electron-withdrawing trifluoromethyl group enhances the compound's stability and potency, making it a valuable component in drug development.
Used in Research Chemicals:
In the field of research chemicals, 1-(2-Trifluoromethylphenyl)-piperazine serves as a valuable compound for studying its antipsychotic and anxiolytic effects in preclinical studies. Its unique structure and properties allow researchers to explore its potential applications in the development of new therapeutic agents.

Upstream product

• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 
• 88-17-5 2-(trifluoromethyl)benzenamine 
• 392-83-6 o-trifluoromethylphenyl bromide 
• 1121596-52-8 tert-butyl 4-(2-(trifluoromethyl)-phenyl)piperazine-1-carboxylate 
• 110-85-0 piperazine 
• 392-85-8 1-fluoro-2-trifluoromethylbenzene 

Downstream Products

• 74765-80-3 1-[4-(2-trifluoromethyl-phenyl)-piperazin-1-yl]-3-(3,4,5-trimethoxy-phenoxy)-propan-2-ol 
• 763915-83-9 1-{2-hydroxy-3-[4-(2-trifluoromethylphenyl)piperazin-1-yl]-propyl}pyrrolidin-2-one 
• 1043476-31-8 C₂₁H₂₅F₃N₂O₂S 

Relevant academic research and scientific papers

Heteroaromatic acetamide derivative, preparation and applications thereof

The present invention provides a heteroaromatic acetamide derivative, a preparation and applications thereof, wherein the derivative comprises a pharmaceutically acceptable salt and/or a solvate thereof. According to the present invention, the experiment results prove that the heteroaromatic acetamide derivative can specifically bind to transient receptor potential ankyrin 1 (TRPA1) and inhibit orreduce the activity of TRPA1, and can be used for treating diseases mediated by TRPA1; and the inhibitor of the present invention further comprises a pharmaceutical composition of the compound, and amethods for preparing the compounds. The derivative has a general formula defined in the specification.

PYRIDAZINONES AND METHODS OF USE THEREOF

Disclosed are compounds according to Formula (A), and related tautomers and pharmaceutical compositions. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (A).

Identification of novel GLUT inhibitors

The compound class of 1H-pyrazolo[3,4-d]pyrimidines was identified using HTS as very potent inhibitors of facilitated glucose transporter 1 (GLUT1). Extensive structure–activity relationship studies (SAR) of each ring system of the molecular framework was established revealing essential structural motives (i.e., ortho-methoxy substituted benzene, piperazine and pyrimidine). The selectivity against GLUT2 was excellent and initial in vitro and in vivo pharmacokinetic (PK) studies are encouraging.

Practical method for parallel synthesis of diversely substituted 1-phenylpiperazines

A simple and practical method to prepare 'libraries' of substituted 1-phenylpiperazine building blocks in parallel format has been developed.

Discovery and Initial SAR of Arylsulfonylpiperazine Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1)

High-throughput screening of a small-molecule compound library resulted in the identification of a series of arylsulfonylpiperazines that are potent and selective inhibitors of human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1). Optimization of the initial lead resulted in the discovery of compound (R)-45 (11β-HSD1 IC50 = 3 nM).

N-Arylpiperazinyl-N'-propylamino derivatives of heteroaryl amides as functional uroselective α1-adrenoceptor antagonists

Novel arylpiperazines were identified as α1-adrenoceptor (AR) subtype- selective antagonists by functional in vitro screening. 3-[4-(ortho- Substituted phenyl)piperazin-1:yl]propylamines were derivatized with N,N- dimethyl anthranilamides, nicotinamides, as well as carboxamides of quinoline, 1,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4- b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta were used as a 'negative screen' for the test antagonists. Binding to α1-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g. 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the α1-AR subtype prevalent in the human lower urinary tract (pA2 values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the α(1D)-AR.

Antiviral agents

Antiviral compounds (I): the symbols being as defined in the specification, are efficacious against infections caused by a variety of DNA viruses, RNA viruses and retroviruses. Other specified compounds also exhibit activity. The compounds have a wider spectrum of activity than known antiviral substances.